Johnson & Johnson (NYSE: JNJ) has announced the FDA‘s approval of TREMFYA® (guselkumab) for adults with moderately to ...

Some patients with psoriasis who were treated with guselkumab and achieved complete skin clearance experienced a persistent impact on quality of life.

Approval of the dual-acting interleukin (IL)-23 inhibitor in ulcerative colitis was based on findings from QUASAR, an ongoing ...

Johnson & Johnson JNJ announced that the FDA approved its blockbuster immunology medicine, Tremfya (guselkumab), for a third ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of adults with ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

17 news release by the university. The drug, guselkumab, marketed under the brand name Tremfya, was approved Sept. 11, according to the release. The first dose was administered Sept. 17 to a ...

Tremfya is a prescription drug used for psoriasis and psoriatic arthritis. Find out about possible interactions with alcohol, ...

Johnson & Johnson (JNJ) said that the U.S. Food and Drug Administration has approved TREMFYA (guselkumab) for the treatment of adults ...

Suggested remit: To appraise the clinical and cost effectiveness of guselkumab within its marketing authorisation for treating moderately to severely active ulcerative colitis.

Johnson & Johnson has announced that the US FDA has approved TREMFYA for the treatment of active ulcerative colitis (UC).